New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term ...

A once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...